FrancophonIA/ELRC3.0 huggingface dataset:
English: The veterinary medicinal product may cause skin sensitisation and persons with a known hypersensitivity to cabergoline or any of the excipients should avoid contact with it.
Estonian: Inimesed, kes on kabergoliini või ravimi ükskõik milliste abiainete suhtes ülitundlikud, peaksid sellega kokkupuudet vältima.
English: DOSAGE FOR EACH SPECIES, ROUTE AND METHOD OF ADMINISTRATION
Estonian: ANNUSTAMINE LOOMALIIGITI, MANUSTAMISVIIS(ID) JA -MEETOD Intramuskulaarne.
English: What measures are being taken to ensure the safe and effective use of Emend?
Estonian: Mis meetmed võetakse, et tagada Emendi ohutu ja efektiivne kasutamine?
English: The European Commission granted a marketing authorisation valid throughout the European Union for Emend on 11 November 2003.
Estonian: Euroopa Komisjon andis Emendi müügiloa, mis kehtib kogu Euroopa Liidu territooriumil, 11. novembril
English: A risk management plan has been developed to ensure that Emend is used as safely as possible.
Estonian: Töötati välja riskijuhtimiskava, et tagada Emendi võimalikult ohutu kasutamine.
English: The full EPAR for Emend can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
Estonian: Euroopa avaliku hindamisaruande täistekst Emendi kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
English: What is Emend?
Estonian: Mis on Emend?
English: Emend is a neurokinin 1 (NK1) receptor antagonist.
Estonian: Emend on neurokiniin-1 (NK1) retseptori antagonist.
English: When substance P attaches to these receptors, it causes nausea and vomiting.
Estonian: Kui P-aine kinnitub nendele retseptoritele, põhjustab see iiveldust ja oksendamist.
English: Other information about Emend
Estonian: Muu teave Emendi kohta
English: • pimozide (used to treat mental illness);
Estonian: • pimosiid (vaimuhaiguste ravim);
English: Emend makes chemotherapy more tolerable for the patient.
Estonian: Emend muudab keemiaravi patsiendile talutavamaks.
English: This is a summary of the European public assessment report (EPAR) for Emend.
Estonian: See on ravimi Emend Euroopa avaliku hindamisaruande kokkuvõte.
English: Emend 80 mg and 125 mg must not be taken with the following medicines:
Estonian: Emendi 80 mg ja 125 mg annust ei tohi manustada koos järgmiste ravimitega:
English: The CHMP decided that Emend's benefits are greater than its risks and recommended that it be given marketing authorisation.
Estonian: Inimravimite komitee otsustas, et Emendi kasulikkus on suurem kui sellega kaasnevad riskid, ja soovitas anda ravimi müügiloa.
English: Why has Emend been approved?
Estonian: Miks Emend heaks kiideti?
English: Emend is a medicine containing the active substance aprepitant.
Estonian: Emend on ravim, mis sisaldab toimeainena aprepitanti.
English: What benefit has Emend shown during the studies?
Estonian: Milles seisneb uuringute põhjal Emendi kasulikkus?
English: After chemotherapy, one 80 mg capsule is taken each day for the next two days.
Estonian: Pärast keemiaravi võetakse kahel järgmisel päeval üks 80 mg kapsel.
English: • terfenadine, astemizole (commonly used to treat allergy symptoms - these medicines may be available without a prescription);
Estonian: • terfenadiin, astemisool (allergiasümptomite tavalised ravimid, mis võivad olla käsimüügiravimid);
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Emend, including the appropriate precautions to be followed by healthcare professionals and patients.
Estonian: Selle alusel lisati Emendi omaduste kokkuvõttesse ja pakendi infolehele ravimi ohutusteave, kus on ka tervishoiuspetsialistide ja patsientide võetavad meetmed.
English: For more information about treatment with Emend, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Emendiga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: It is only given on the first day of the chemotherapy and is followed by treatment involving a corticosteroid and a 5HT3 antagonist.
Estonian: Kapsel antakse vaid keemiaravi esimesel päeval ning sellele järgneb ravi kortikosteroidi ja 5-HT3 antagonistiga.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Emend.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: Emend was also shown to be effective in the first 24 hours after chemotherapy.
Estonian: Emend oli efektiivne ka esimese 24 tunni jooksul pärast keemiaravi.
English: In children between 6 months and 12 years of age, Emend oral suspension is given together with a 5HT3 antagonist.
Estonian: Lastele alates 6. elukuust kuni 12. eluaastani manustatakse Emendi suukaudset lahust koos 5-HT3 antagonistiga.
English: The first two studies involved a total of 1,094 adults receiving chemotherapy including cisplatin, and the third involved 866 adults with breast cancer who were receiving cyclophosphamide, with or without doxorubicin or epirubicin.
Estonian: Esimeses kahes uuringus osales 1094 täiskasvanud patsienti, kes said keemiaravi tsisplatiiniga, ja kolmandas osales 866 rinnavähiga patsienti, kes said tsüklofosfamiidi koos doksorubitsiini või epirubitsiiniga või ilma.
English: This is nausea and vomiting that a patient can experience after surgery.
Estonian: Need on iiveldus ja oksendamine, mis võivad esineda patsientidel pärast operatsiooni.
English: In the chemotherapy studies in adults, adding Emend to the standard combination was more effective than the standard combination alone.
Estonian: Keemiaravi uuringutes täiskasvanutel andis Emendi lisamine tavalisele ravimikombinatsioonile parema tulemuse kui tavaline ravimikombinatsioon ilma Emendita.
English: Emend 165 mg is given to adults only once, one hour before the start of chemotherapy.
Estonian: Emendi 165 mg kapsel antakse täiskasvanutele vaid üks kord - tund enne keemiaravi algust.
English: The dose of Emend oral suspension to be given depends on the patient's bodyweight.
Estonian: Emendi suukaudse lahuse annus sõltub patsiendi kehakaalust.
English: The main measure of effectiveness was the number of patients who had no nausea and vomiting in the five days after receiving chemotherapy.
Estonian: Efektiivsuse põhinäitaja oli patsientide arv, kellel ei esinenud viie päeva jooksul pärast keemiaravi iiveldust ja oksendamist.
English: It is used with chemotherapy that is a moderate or high trigger of nausea and vomiting such as cisplatin, cyclophosphamide, doxorubicin or epirubicin.
Estonian: Seda kasutatakse koos keemiaravi ravimitega, mis vallandavad mõõduka või tugeva iivelduse ja oksendamise, näiteks tsisplatiin, tsüklofosfamiid, doksorubitsiin või epirubitsiin.
English: Emend oral suspension is given one hour before the start of chemotherapy, and for the next 2 days.
Estonian: Emendi suukaudne lahus manustatakse üks tund enne keemiaravi algust ja kahel järgneval päeval.
English: By blocking the receptors, Emend can prevent nausea and vomiting, which often happens after chemotherapy or as a complication of surgery.
Estonian: Blokeerides need retseptorid, ennetab Emend iiveldust ja oksendamist, mis tekib sageli pärast keemiaravi või operatsiooni tüsistusena.
English: In PONV, two studies were carried out in a total of 1,727 adult patients, most of whom were women undergoing gynaecological operations.
Estonian: Operatsioonijärgse iivelduse ja oksendamise uuringuid viidi läbi kaks; neis osales kokku 1727 täiskasvanud patsienti, enamikus naised, kellele oli tehtud günekoloogiline operatsioon.
English: The effectiveness of Emend was also seen during a further five cycles of chemotherapy.
Estonian: Emendi efektiivsus ilmnes ka keemiaravi viie tsükli kestel.
English: It must be given with other medicines that also prevent nausea and vomiting, including a corticosteroid (such as dexamethasone) and a ‘5-HT3 antagonist' (such as ondansetron).
Estonian: Emendit peab alati võtma koos teiste iiveldust ja oksendamist ennetavate ravimitega, sealhulgas kortikosteroid (näiteks deksametasoon) ja 5-HT3 antagonist (näiteks ondansetroon).
English: Emend 80, 125 and 165 mg capsules are used in adults; children from 12 years of age may be given the 80- or 125-mg capsules and children between 6 months and 12 years of age are given the oral suspension.
Estonian: Emendi 80, 125 ja 165 mg kapsleid kasutatakse täiskasvanutel; lastele alates 12. eluaastast võib anda 80 või 125 mg kapsleid ja lastele alates 6. elukuust kuni 12. eluaastani suukaudset lahust.
English: Emend is used with other medicines to prevent nausea and vomiting caused by chemotherapy (medicines used to treat cancer).
Estonian: Emendit kasutatakse koos teiste ravimitega, et ennetada iiveldust ja oksendamist, mida põhjustab keemiaravi (vähiravimid).
English: Tests were performed to determine that Emend 165 mg produces the same amount of aprepitant in the body as a single dose of 150 mg Ivemend.
Estonian: Katsetega püüti kindlaks teha, kas Emendi 165 mg annus tekitab organismis samasuguse aprepitandisisalduse kui Ivemendi 150 mg üksikannus.
English: It is available as capsules (40, 80, 125 and 165 mg) and as a powder to be made up into an oral (by mouth) suspension (125 mg).
Estonian: Seda turustatakse kapslitena (40, 80, 125 ja 165 mg) ja suukaudse lahuse pulbrina (125 mg).
English: At a dose of 80, 125 and 165 mg, the other side effects seen in between 1 and 10 patients in 100 are headache, hiccups, constipation, dyspepsia (indigestion), loss of appetite, and fatigue (tiredness).
Estonian: 80, 125 ja 165 mg annuse muud kõrvalnähud (esinenud 1-10 patsiendil 100st) olid peavalu, luksumine, kõhukinnisus, düspepsia (seedehäired), anoreksia (isutus) ja väsimus.
English: Emend 165 mg capsules were shown to be bioequivalent to Ivemend 150 mg, which means that like Ivemend it can also be used to prevent nausea and vomiting caused by chemotherapy.
Estonian: Emendi 165 mg kapslid osutusid Ivemendi 150 mg annusega bioekvivalentseks, mis tähendab, et seda saab sarnaselt Ivemendile kasutada iivelduse ja oksendamise ennetamiseks keemiaravi patsientidel.
English: What is the risk associated with Emend?
Estonian: Mis riskid Emendiga kaasnevad?
English: All three studies compared the effectiveness of Emend, taken in combination with dexamethasone and ondansetron, with that of the standard combination of dexamethasone and ondansetron.
Estonian: Kõigis kolmes uuringus võrreldi Emendi ning deksametasooni ja ondansetrooni kombinatsioonravi efektiivsust tavalise, ainult deksametasooni ja ondansetrooni sisaldava ravi efektiivsusega.
English: In PONV, Emend was as effective as ondansetron.
Estonian: Operatsioonijärgse iivelduse ja oksendamise uuringutes oli Emend sama tõhus kui ondansetroon.
English: In chemotherapy, the usual dose of Emend in adults and children from 12 years of age is one 125 mg capsule by mouth one hour before the start of chemotherapy.
Estonian: Keemiaravis on Emendi tavaline annus täiskasvanutel ja vähemalt 12-aastastel lastel üks suukaudne 125 mg kapsel üks tund enne keemiaravi algust.
English: For the full list of restrictions with Emend, see the package leaflet.
Estonian: Emendi kohta teatatud piirangute täielik loetelu on pakendi infolehel.
English: A fourth study has been carried out with Emend (125 mg capsules or 125 mg oral solution) in 307 children from 6 months to 17 years of age, where Emend, taken with ondansetron (with or without dexamethasone), was compared with ondansetron alone (with or without dexamethasone).
Estonian: Neljandas Emendi (125 mg kapslid või 125 mg suukaudne lahus) uuringus, kus osales 307 last alates 6. elukuust kuni 17. eluaastani, võrreldi Emendi ja ondansetrooni kombinatsiooni (deksametasooniga või ilma) ja ondansetrooni monoteraapiat (deksametasooniga või ilma).
English: It stops a chemical in the body (substance P) from binding to the NK1 receptors.
Estonian: Ravim takistab organismi teatud kemikaali (Paine) kinnitumist NK1-retseptoritele.
English: Emend 40 mg capsules are used to prevent postoperative nausea and vomiting (PONV) in adults.
Estonian: Emendi 40 mg kapsleid kasutatakse täiskasvanutel operatsioonijärgse iivelduse ja oksendamise ennetamiseks.
English: The most common side effect of Emend at all doses in adults (seen in between 1 and 10 patients in 100) is increased liver enzymes.
Estonian: Emendi kõige sagedam kõrvaltoime (esinenud 1-10 patsiendil 100st) oli maksaensüümide sisalduse suurenemine.
English: The studies measured how many patients had a complete response, which was defined as no vomiting and no need for any other medication to control nausea and vomiting in the 24 hours after the operation.
Estonian: Uuringutes vaadeldi täieliku ravivastusega patsientide arvu (täielikuks ravivastuseks loeti seda, kui 24 tunni jooksul pärast operatsiooni patsient ei oksendanud ega vajanud iivelduse ja oksendamise vastu ravimeid).
English: In the study in children, around 51% (77 out of 152) of children given Emend with ondansetron had a complete response 25 to 120 hours after beginning chemotherapy, compared with 26% (39 out of 150) of children given ondansetron alone.
Estonian: Laste uuringus tekkis 25-120 tunni jooksul pärast keemiaravi algust täielik ravivastus umbes 51%-l lastest (77 patsienti 152-st), kes said Emendit koos ondansetrooniga, ning 26%-l kontrollrühma lastest (39 patsienti 150-st), kes said ainult ondansetrooni.
English: What is Emend used for?
Estonian: Milleks Emendit kasutatakse?
English: In children, the most common side effects are hiccups and flushing.
Estonian: Lastel olid sagedamad kõrvalnähud luksumine ja nahapunetus.
English: In PONV, the usual dose is one 40 mg capsule given to adults within the three hours before the patient is anaesthetised (‘put to sleep').
Estonian: Operatsioonijärgse iivelduse ja oksendamise korral on tavaline annus üks 40 mg kapsel, mis antakse täiskasvanud patsiendile kolm tundi enne tema viimist anesteesiasse (narkoosi).
English: In the study of chemotherapy that is a moderate trigger of nausea and vomiting, 51% of the patients taking Emend had no nausea or vomiting (220 out of 433), compared with 43% of the patients who did not take it (180 out of 424).
Estonian: Mõõdukalt iiveldust ja oksendamist põhjustava keemiaravi uuringus ei esinenud iiveldust ja oksendamist Emendi ravirühmas 51%-l patsientidest (220 patsienti 433-st), kontrollrühma tulemus oli 43% (180 patsienti 424-st).
English: For the full list of all side effects reported with Emend, see the package leaflet.
Estonian: Emendi kohta teatatud kõrvalnähtude täielik loetelu on pakendi infolehel.
English: Looking at the results of the two cisplatin studies taken together, 68% of the patients taking Emend had no nausea or vomiting over five days (352 out of 520), compared with 48% of the patients who did not take it (250 out of 523).
Estonian: Kahes tsisplatiini uuringus kokku ei esinenud viie päeva jooksul iiveldust ja oksendamist Emendi ravirühmas 68%-l patsientidest (352 patsienti 520-st), kontrollrühma tulemus oli 48% (250 patsienti 523-st).
English: Looking at the results of both studies together, 55% of the patients (298 out of 541) taking Emend capsules at a dose of 40 mg had a complete response, compared with 49% of the patients who received ondansetron (258 out of 526).
Estonian: Mõlema uuringu koondnäitajad olid järgmised: Emendit annuses 40 mg saanud patsientidest tekkis täielik ravivastus 55%-l (298 patsienti 541-st), ondansetrooni ravirühmas 49%-l (258 patsienti 526st).
English: Emend is an antiemetic, a medicine that prevents nausea (feeling sick) and vomiting.
Estonian: Emend on antiemeetikum, iiveldust ja oksendamist ennetav ravim.
English: The main measure of effectiveness was based on how many patients had a ‘complete response', which was defined as no vomiting, retching or dry heaves and no need for any other medication to control nausea and vomiting 25 to 120 hours after the start of chemotherapy (delayed phase).The study also looked at how many patients achieved a complete response in the first 24 hours after chemotherapy (acute phase).
Estonian: Efektiivsuse põhinäitaja oli patsientide arv, kellel tekkis täielik ravivastus, milleks loeti seda, kui 25-120 tundi pärast keemiaravi algust (hilisfaas) patsient ei oksendanud, öökinud ega vajanud iivelduse ja oksendamise vastast ravi.
English: Two doses of Emend (40 and 125 mg as capsules) were compared with ondansetron given as an injection.
Estonian: Uuringutes võrreldi Emendi kahe annuse (40 mg ja 125 mg kapslid) mõju süstina manustatud ondansetrooni mõjuga.
English: How is Emend used?
Estonian: Kuidas Emendit kasutatakse?
English: How does Emend work?
Estonian: Kuidas Emend toimib?
English: The medicine can only be obtained with a prescription.
Estonian: Emend on retseptiravim.
English: In chemotherapy, three main studies have been carried out for Emend 80 and 125 mg capsules.
Estonian: Emendi 80 ja 125 mg annustega tehti keemiaravi patsientidel kolm põhiuuringut.
English: Emend 165 mg capsules were compared with the authorised intravenous medicine Ivemend 150 mg. Ivemend contains a substance called fosaprepitant which is converted in the body into aprepitant.
Estonian: Emendi 165 mg kapsleid võrreldi müügiloaga veenisisese ravimi Ivemend 150 mg annusega.
English: How has Emend been studied?
Estonian: Kuidas Emendit uuriti?
English: EU/1/17/1232/001 Miglustat Gen.Orph
Estonian: EU/1/17/1232/001 Miglustat Gen.Orph 100 mg Kõvakapsel
English: Blister (OPA/alu/PVC) 84 capsules
Estonian: Blister (OPA/alumiinium/PVC)
English: 100 mg Capsule, hard
Estonian: 84 kapslit
English: 19 April 2012
Estonian: 19. aprill 2012
English: What is Folotyn?
Estonian: Mis on Folotyn?
English: The CHMP therefore confirmed its initial negative opinion.
Estonian: Sel põhjusel kinnitas inimravimite komitee oma algset negatiivset arvamust.
English: The summary of the opinion of the Committee for Orphan Medicinal Products for Folotyn can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
Estonian: Harvikravimite komitee arvamuse kokkuvõte Folotyni kohta on ameti veebilehel: ema.europa.eu/Find medicine/Human medicines/Rare disease designation.
English: If you are in a clinical trial or compassionate use programme and need more information about your treatment, contact the doctor who is giving it to you.
Estonian: Kui osalete kliinilises uuringus või eriloaga kasutamise programmis ja vajate oma oma ravi kohta lisateavet, siis pöörduge palun arsti poole, kes teile ravi määras.
English: DHFR is necessary for the production of new DNA, which is required for cells to divide and multiply.
Estonian: DHFR on vajalik uue DNA tootmiseks, mida rakud vajavad jagunemiseks ja paljunemiseks.
English: The main measure of effectiveness was based on the proportion of patients who responded to treatment.
Estonian: Efektiivsuse põhinäitaja oli ravile allunud patsientide suhtarv.
English: Moreover, there was no clear improvement seen in the condition of the patients, as the study looked at the patients' response to treatment but did not further allow the Committee to assess the effect on overall survival (how long the patients lived) or progression free survival (how long the patients lived without their disease getting worse).
Estonian: Lisaks ei täheldatud patsientide seisundis selget paranemist, sest uuring vaatles patsientide ravivastust, kuid ei võimaldanud inimravimite komiteel hinnata mõju üldisele elulemusele või progresseerumisvabale elulemusele (kui kaua patsiendid elus olid, ilma et nende haigus süveneks).
English: After considering the grounds for this request, the CHMP re-examined the initial opinion, and confirmed the refusal of the marketing authorisation on 19 April 2012.
Estonian: Pärast taotluse põhjenduste kaalumist vaatas inimravimite komitee oma algse arvamuse uuesti läbi ja kinnitas müügiloa andmisest keeldumist 19. aprillil 2012.
English: Refusal of the marketing authorisation for Folotyn (pralatrexate)
Estonian: Folotyni (pralatreksaat) müügiloa andmisest keeldumine
English: Refusal of the marketing authorisation for Folotyn (pralatrexate) EMA/CHMP/255106/2012
Estonian: Folotyni (pralatreksaat) müügiloa andmisest keeldumine EMA/CHMP/255106/2012
English: Patients were given Folotyn together with vitamin B12 and folic acid supplements (to compensate for the deficiency in these vitamins that may occur during Folotyn treatment).
Estonian: Patsientidele anti Folotyni koos foolhappe ja vitamiiniga B12 (et kompenseerida nende vitamiinide puudust, mis võib esineda ravi ajal Folotyniga).
English: During the re-examination in April 2012, the CHMP's concerns were not resolved.
Estonian: Taasläbivaatamise ajal aprillis 2012 ei olnud inimravimite komitee leitud probleemid lahenenud.
English: The company that applied for the authorisation is Allos Therapeutics Limited.
Estonian: Müügiluba taotles ettevõte Allos Therapeutics Limited.
English: The company presented the results of one main study involving a total of 115 adults with peripheral Tcell lymphoma which kept coming back or did not respond to previous treatments.
Estonian: Ettevõte esitas ühe põhiuuringu andmed, milles osales kokku 115 täiskasvanut, kellel oli perifeerne T-rakuline lümfoom, mis taastekkis või ei allunud eelnevale ravile.
English: In this study, Folotyn was not compared with any other treatment.
Estonian: Selles uuringus ei võrreldud Folotyni ühegi muu ravimeetodiga.
English: Therefore, at that point in time, the CHMP was of the opinion that the benefits of Folotyn did not outweigh its risks and recommended that it be refused marketing authorisation.
Estonian: Seetõttu oli inimravimite komitee sel ajal arvamusel, et ravimi Folotyn kasulikkus ei ole suurem kui kaasnevad riskid ja soovitas müügiloa andmisest keelduda.
English: Folotyn is a medicine that contains the active substance pralatrexate.
Estonian: Folotyn on ravim, mis sisaldab toimeainena pralatreksaati.
English: In the body, it is expected to take the place of folic acid and attach to an enzyme called dihydrofolate reductase (DHFR).
Estonian: Organismis eeldatakse, et see võtab foolhappe koha ja kinnitub dihüdrofolaatreduktaasiks (DHFR) nimetatava ensüümi külge.
English: In January 2012, the CHMP was concerned that the main study was designed in a way that did not allow the Committee to assess the benefit of the medicine, particularly since Folotyn was not compared with any other treatment or placebo (a dummy treatment) in another group of patients.
Estonian: 2012. aasta jaanuaris leidis inimravimite komitee, et põhiuuringu ülesehitus ei võimaldanud komiteel hinnata ravimi kasulikkust, sest Folotyni ei võrreldud teises patsientide rühmas ühegi muu ravimi ega platseeboga (näiv ravim).
English: expected to block the enzyme's activity, inhibiting the division of the cancer cells and eventually killing them.
Estonian: Eeldatakse, et DHFRi külge kinnitudes blokeerib pralatreksaat ensüümi aktiivsuse, pärssides vähirakkude jagunemist ja lõpuks hävitades need.
English: Folotyn was expected to be used to treat adults with peripheral T-cell lymphoma, which is a cancer of a type of white blood cell called T-cells.
Estonian: Folotyni kavatseti kasutada täiskasvanute raviks, kellel esineb perifeerne T-rakuline lümfoom, mis on teatud vere valgeliblede T-rakkude vähk.
English: In particular, the Committee considered that the data submitted by the applicant were insufficient to establish the benefits of Folotyn in the treatment of peripheral T-cell lymphoma.
Estonian: Eriti leidis komitee, et taotleja esitatud andmed Folotyni kasulikkuse kindlakstegemiseks perifeerse T-rakulise lümfoomi ravis ei ole piisavad.
English: It was to be available as a solution for infusion (drip into a vein).
Estonian: Ravimit kavatseti turustada infusioonilahusena (veeni tilgutatav lahus).
English: The effects of Folotyn were first tested in experimental models before being studied in humans.
Estonian: Enne inimuuringuid kontrolliti Folotyni toimet muude katsetega.